Efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors for Chinese patients with squamous cell carcinoma of lung harboring EGFR mutation
Efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors for Chinese patients with squamous cell carcinoma of lung harboring EGFR mutation
复制标题
表皮生长因子受体酪氨酸激酶抑制剂对中国携带 EGFR 突变的肺鳞状细胞癌患者的疗效。
DOI：
10.3978/j.issn.2072-1439.2013.09.15
复制
发表时间：
2013-10-01
影响因子：
2.5
通讯作者：
Zhang, Li
中科院分区：
文献类型：
--
作者：
Fang, Wenfeng;Zhang, Jianwei;Zhang, Li
目的：表皮生长因子受体（EGFR）突变多见于肺腺癌，在肺鳞癌中少见。在以往的报告中，SQCC的EGFR突变率各不相同，EGFR酪氨酸激酶抑制剂（TKI）在携带EGFR突变的SQCC中的疗效尚未得到充分评价。本研究的目的是探讨EGFR-TKI对中国肺SQCC携带EGFR突变患者的疗效。第一个队列包括2008年1月至2012年10月的146例连续术后SQCC患者。第二个队列包括63例接受EGFR-TKI治疗的晚期SQCC患者。采用Real-time PCR方法检测EGFR基因突变。对携带活化EGFR突变的患者，采用免疫组化（IHC）验证病理诊断。结果：在第一队列146例手术切除的患者中，3例患者检测到EGFR突变，突变率为2.0%。在队列2中，63例接受EGFR-TKI治疗的患者中，15例患者具有活化的EGFR突变。有效率为26.7%，疾病控制率为66.7%。5例患者疾病控制超过6个月。EGFR突变患者的无进展生存期（PFS）为3.9个月。结论：在中国SQCC患者中，EGFR突变率极低。EGFR-TKI在EGFR突变的SQCC患者中似乎不太有效，但一些患者仍然可以从EGFR-TKI中获益。为了确定这部分患者，未来需要进一步研究。
Objective: Epidermal growth factor receptor (EGFR) mutation mostly occurred in lung adenocarcinoma, rarely in squamous cell carcinoma (SQCC). EGFR mutation rate in SQCC varied in previous reports, and the efficacy of EGFR tyrosine kinase inhibitors (TKIs) in SQCC harboring EGFR mutation has not yet been fully evaluated. The aim of this study was to investigate the efficacy EGFR-TKIs for Chinese patients with SQCC of lung harboring EGFR mutation.Patients and methods: Two cohorts of patients were analyzed. The first cohort included 146 consecutive post-operation SQCC patients from January 2008 to October 2012. The second cohort included 63 patients with advanced SQCC receiving EGFR-TKIs treatment. EGFR mutation analysis was performed with Real-time PCR method. The pathologic diagnosis was validated with immunohistochemistry (IHC) for patients harboring activated EGFR mutation. And the efficacy of EGFR-TKIs in squamous cell carcinoma of lung (SQCC) was evaluated in patients with activated EGFR mutations.Results: In the first cohort, 146 resected patients, EGFR mutations were detected in 3 patients, with the mutation rate of 2.0%. In cohort two, 63 patients treated with EGFR-TKIs, 15 patients possessed activated EGFR mutations. The response rate and disease control rate in these patients was 26.7% and 66.7% respectively. 5 patients had disease control over 6 months. The progression free survival (PFS) in EGFR-mutated patients was 3.9 months.Conclusions: In Chinese SQCC patients, EGFR mutation rate was extremely low. EGFR-TKIs seemed to be less effective in EGFR-mutated SQCC patients, but some patients could still obtain benefit from EGFR-TKIs. To identify this part of patients, further study was warranted in the future.